Q1 2023 Results and presentation

Tromsø, Norway, 03rd May 2023 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 31.2 million and an EBITDA of NOK 6.1 million for the first quarter of 2023. Highlights from Q1 2023 ArcticZymes Technologies (AZT) had Q1 sales of NOK 31.2 million (Q1 2022: NOK 49.2 million, NOK 35.2 million adjusted for Covid effects in Q1 2022) AZT had …

Invitation to presentation of Q1 2023results

The Company will host a presentation for investors, analysts and media at 08:30 a.m on Thursday, 4 May 2023 at Hotel Continental, Stortingsgata 24/26, Oslo. The presentation will be given by Chairman of the Board, Marie Roskrow and CFO, Børge Sørvoll The presentation can also be followed as a live webcast from Hegnar TV on www.arcticzymes.com or https://channel.royalcast.com/landingpage/hegnarmedia/20230504_5//. It will be possible …

ArcticZymes Technologies launches ArcticZymes Proteinase HQ

Tromsø, Norway, April 18nd 2023 – ArcticZymes Technologies ASA (OSE:AZT) announces the launch of ArcticZymes Proteinase HQ to the B2B market. Following up on earlier press-releases (9th Dec 2022) ArcticZymes is pleased to launch the latest member in our Proteinase product portfolio: ArcticZymes Proteinase HQ. This product is the ‘bioprocessing grade’ version of our existing successful ArcticZymes Proteinase and will be …

ArcticZymes Technologies announces CEO resignation

Tromso, March 22nd 2023 – ArcticZymes Technologies ASA (OSE: AZT) announces that the Board of Directors has today accepted the voluntary resignation of Jethro Holter as Chief Executive Officer, due to personal reasons. The resignation will take effect on 30th September 2023 after the required 6 months notice period. “On behalf of the Board, I want to thank Jethro very …